pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·59m ago·1 min read
save

Epic’s dominance forces health-care AI firms to adapt, new STAT+ analysis finds

Oct 28, 2026·read at STAT ↗Neutral

The latest STAT+ AI Prognosis newsletter examines how Epic’s entrenched position in electronic health-record systems is shaping the strategies of health-care artificial-intelligence companies. The piece argues that Epic’s market share creates both barriers and incentives for AI developers, who must design products that can integrate with Epic’s platform or risk limited adoption.

The analysis highlights that many startups are now prioritizing compatibility with Epic’s APIs and data standards, even as some critics warn that reliance on a single vendor could stifle innovation. The author notes that Epic’s influence extends beyond software, affecting data governance and the pace at which new AI tools can be deployed in clinical settings.

While the newsletter does not present new data, it underscores the strategic importance of navigating Epic’s ecosystem for any firm seeking to scale AI solutions in health care. The discussion is framed as a call to action for AI companies to engage with Epic’s ecosystem rather than ignore it.

Overall, the article positions Epic’s market dominance as a pivotal factor that health-tech firms must consider in product development and partnership strategies.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Why every health care AI company must face Epic”

read at STAT ↗
462 words · retrieved 42m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2h agoSTAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and moreSTAT
  • 2h agoSTAT+: Lilly’s triple-G drug beats Ozempic in head-to-head studySTAT
  • 3h agoWhat has actually caused the decline in drug overdose deaths?STAT
  • 5h agoSTAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes studySTAT
  • 7h agoSTAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technologySTAT